Pieris Depreciation vs End Period Cash Flow Analysis

PIRS Stock  USD 16.83  0.24  1.41%   
Pieris Pharmaceuticals financial indicator trend analysis is much more than just breaking down Pieris Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pieris Pharmaceuticals is a good investment. Please check the relationship between Pieris Pharmaceuticals Depreciation and its End Period Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.

Depreciation vs End Period Cash Flow

Depreciation vs End Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pieris Pharmaceuticals Depreciation account and End Period Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Pieris Pharmaceuticals' Depreciation and End Period Cash Flow is 0.55. Overlapping area represents the amount of variation of Depreciation that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Pieris Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Pieris Pharmaceuticals' Depreciation and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation of Pieris Pharmaceuticals are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Depreciation i.e., Pieris Pharmaceuticals' Depreciation and End Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.55
Relationship DirectionPositive 
Relationship StrengthWeak

Depreciation

Depreciation indicates how much of Pieris Pharmaceuticals value has been used up. For tax purposes Pieris Pharmaceuticals can deduct the cost of the tangible assets it purchases as business expenses. However, Pieris Pharmaceuticals must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

End Period Cash Flow

Most indicators from Pieris Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pieris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.Issuance Of Capital Stock is likely to gain to about 22.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 13.5 M in 2024.
 2021 2022 2023 2024 (projected)
Net Interest Income4K721K1.7M936.8K
Interest Income4K721K1.7M1.8M

Pieris Pharmaceuticals fundamental ratios Correlations

0.70.40.90.80.52-0.89-0.490.770.920.680.740.490.980.550.70.550.910.180.450.660.970.970.060.330.9
0.70.040.530.760.49-0.63-0.560.50.630.590.770.50.680.390.860.730.70.20.50.680.590.710.550.310.67
0.40.040.50.320.48-0.48-0.520.440.490.440.140.360.38-0.10.410.220.350.570.590.540.380.39-0.480.740.28
0.90.530.50.540.35-0.8-0.430.60.790.530.470.280.890.670.60.440.80.250.390.560.950.880.040.380.84
0.80.760.320.540.64-0.8-0.620.820.820.640.850.560.810.130.780.680.730.330.650.740.630.830.160.390.67
0.520.490.480.350.64-0.41-0.910.650.490.920.780.910.430.080.740.720.710.720.860.870.420.54-0.240.660.55
-0.89-0.63-0.48-0.8-0.8-0.410.4-0.66-0.98-0.52-0.66-0.4-0.92-0.28-0.62-0.46-0.74-0.17-0.49-0.56-0.83-0.88-0.13-0.29-0.74
-0.49-0.56-0.52-0.43-0.62-0.910.4-0.56-0.43-0.82-0.7-0.76-0.42-0.11-0.85-0.86-0.65-0.88-0.95-0.94-0.39-0.550.09-0.76-0.54
0.770.50.440.60.820.65-0.66-0.560.710.690.690.430.740.340.640.520.740.410.560.670.670.77-0.070.440.66
0.920.630.490.790.820.49-0.98-0.430.710.620.730.50.920.290.640.480.770.180.510.610.850.870.060.30.74
0.680.590.440.530.640.92-0.52-0.820.690.620.810.870.580.340.810.740.820.560.740.880.630.63-0.130.660.67
0.740.770.140.470.850.78-0.66-0.70.690.730.810.760.690.210.80.830.80.390.680.80.620.730.110.290.68
0.490.50.360.280.560.91-0.4-0.760.430.50.870.760.410.010.640.610.670.460.710.740.420.47-0.210.520.52
0.980.680.380.890.810.43-0.92-0.420.740.920.580.690.410.480.660.50.880.120.40.590.950.970.070.290.89
0.550.39-0.10.670.130.08-0.28-0.110.340.290.340.210.010.480.30.180.54-0.04-0.050.190.660.510.350.060.61
0.70.860.410.60.780.74-0.62-0.850.640.640.810.80.640.660.30.910.750.60.80.950.60.710.210.680.66
0.550.730.220.440.680.72-0.46-0.860.520.480.740.830.610.50.180.910.660.680.790.910.430.580.120.530.55
0.910.70.350.80.730.71-0.74-0.650.740.770.820.80.670.880.540.750.660.330.580.740.890.92-0.050.450.97
0.180.20.570.250.330.72-0.17-0.880.410.180.560.390.460.12-0.040.60.680.330.890.740.10.28-0.210.70.23
0.450.50.590.390.650.86-0.49-0.950.560.510.740.680.710.4-0.050.80.790.580.890.880.330.53-0.090.720.47
0.660.680.540.560.740.87-0.56-0.940.670.610.880.80.740.590.190.950.910.740.740.880.550.66-0.040.770.61
0.970.590.380.950.630.42-0.83-0.390.670.850.630.620.420.950.660.60.430.890.10.330.550.920.010.270.9
0.970.710.390.880.830.54-0.88-0.550.770.870.630.730.470.970.510.710.580.920.280.530.660.920.080.350.94
0.060.55-0.480.040.16-0.24-0.130.09-0.070.06-0.130.11-0.210.070.350.210.12-0.05-0.21-0.09-0.040.010.08-0.20.03
0.330.310.740.380.390.66-0.29-0.760.440.30.660.290.520.290.060.680.530.450.70.720.770.270.35-0.20.36
0.90.670.280.840.670.55-0.74-0.540.660.740.670.680.520.890.610.660.550.970.230.470.610.90.940.030.36
Click cells to compare fundamentals

Pieris Pharmaceuticals Account Relationship Matchups

Pieris Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets141.1M105.0M153.6M95.5M38.7M36.7M
Other Current Liab5.0M6.6M15.8M10.7M8.6M6.6M
Total Current Liabilities27.0M22.1M50.6M36.6M11.9M11.3M
Total Stockholder Equity51.4M31.0M50.8M27.9M26.8M28.8M
Property Plant And Equipment Net22.9M26.0M23.0M20.7M23.8M25.0M
Net Debt(46.0M)(53.5M)(103.9M)(25.5M)(17.4M)(18.3M)
Retained Earnings(174.2M)(211.4M)(257.1M)(290.4M)(315.0M)(299.2M)
Accounts Payable10.1M1.8M8.6M4.2M3.4M3.6M
Cash62.3M70.4M117.8M38.6M17.4M16.5M
Non Current Assets Total26.1M29.3M25.9M22.1M25.4M13.5M
Non Currrent Assets Other3.1M3.3M2.9M1.4M1.6M1.1M
Other Assets910K3.1M7.2M2.9M3.3M3.5M
Cash And Short Term Investments104.2M70.4M117.8M59.2M26.4M25.0M
Net Receivables6.8M1.7M3.3M5.8M572K543.4K
Common Stock Total Equity54K55K56K72K82.8K42.7K
Common Stock Shares Outstanding632.8K681.0K806.8K927.2K1.1M674.0K
Liabilities And Stockholders Equity141.1M105.0M153.6M95.5M38.7M36.7M
Non Current Liabilities Total62.7M51.8M52.2M31.0M35.6M30.4M
Other Current Assets4.1M7.2M13.1M8.4M11.7M12.3M
Other Stockholder Equity227.5M242.7M307.0M318.5M341.6M201.9M
Total Liab89.7M74.0M102.8M67.6M11.9M11.3M
Total Current Assets115.0M75.7M127.6M73.4M38.7M69.0M
Common Stock55K56K72K74K98K57.9K
Other Liab47.3M35.9M38.4M18.7M21.5M26.7M
Net Tangible Assets51.4M31.0M50.8M27.9M32.1M31.6M
Current Deferred Revenue11.3M12.6M25.1M20.8M23.9M17.9M
Retained Earnings Total Equity(147.1M)(174.2M)(211.4M)(257.1M)(231.4M)(219.9M)
Short Term Investments34.8M53.2M41.9M20.5M9.0M15.9M
Capital Surpluse189.9M227.5M242.7M307.0M353.0M370.7M
Property Plant And Equipment Gross22.9M22.0M23.0M20.7M23.8M25.0M
Accumulated Other Comprehensive Income(2.0M)(295K)829K(254K)28K29.4K
Non Current Liabilities Other27K62.7M6K52.2M60.1M63.1M
Property Plant Equipment19.5M26.0M23.0M20.7M23.8M25.0M
Net Invested Capital51.4M31.0M50.8M27.9M32.1M39.0M
Net Working Capital88.0M53.6M77.1M36.8M33.2M51.6M
Capital Stock55K56K72K74K85.1K68.4K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Pieris Stock Analysis

When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.